Dogs

Clinical trials for dogs

  • Status:  Currently enrolling

    Description: Congenital heart defects occur in a variety of dog breeds, with the most common being the patent ductus arteriosus (PDA).  Although this is a correctable disorder in most puppies, it requires surgery or a catheter-based procedure which can be expensive and is not without risk.  Therefore, determining the genetic cause of PDA in dogs would be highly desirable so that dogs could be screened and the genetic mutation could be eventually bred out of the canine population.  Corgis are a breed at increased risk for PDAs, so the goal of this study is to evaluate Corgis with and without PDAs in order to identify the gene mutation for this heart problem.

    Inclusion Criteria:                                      

    Pembroke Welsh Corgis with a documented PDA will be studied.

    Exclusion Criteria:

    Breeds other than Pembroke Welsh Corgis.

    Client Benefits:

    The study will cover the cost of an echocardiogram (ultrasound of the heart) as well as a blood sample for DNA testing.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

  •  Sponsor:  Private Foundation

    CSRC Protocol #: 026-14

    Status: Not currently enrolling

    Description:

    Dogs get a disease of the intestine called inflammatory bowel disease (IBD) in which the normal lining of the intestine is replaced by inflammatory white blood cells. This inflammation results in poor digestion,  often manifesting as diarrhea, vomiting, and weight loss, and in some cases, loss of protein through the feces. This leads to a severe protein deficiency in the body, called a protein losing enteropathy (PLE). PLE is typically an indication of very severe intestinal inflammation and dogs with this condition may not respond well to typical medications used to treat IBD. In addition the PLE itself can cause fatal complications such as edema, fluid in the abdominal cavity, and blood clots. There is a need for new therapies to treat dog with PLE secondary to IBD. Based on evidence in the literature from pre-clinical and clinical trials in humans, we hypothesize that treatment of dogs with a PLE from IBD with stem cells isolated from the umbilical cords of dogs will modulate the inflammatory response in the intestine and induce clinical remission.

    The purpose of the study is to determine whether intravenous administration of cells called mesenchymal stem cells can improve your dog’s clinical signs as well as their blood protein levels. It is believed that the benefit of these stem cells is related to their ability to suppress inflammation.

    Inclusion Criteria:

    Dogs will have had incomplete response to therapy with prednisone, budesonide and/or cyclosporine (defined by a clinical score (CCECAI) >5), have intolerable side effects on medication, or have the administration of cyclosporine or chlorambucil be financially unreasonable for the owner, as these are the patients who require alternative therapeutic options.

    Dogs with biopsy confirmed IBD and bloodwork confirmed panhypoproteinemia

    (total protein <5.5 mg/dl) will be enrolled. The biopsies may be performed at Tufts if they are not already available for pathologist review.

    Both male and female dogs weighing greater than 11 pounds and any age will be considered for the study.

    Exclusion Criteria:

    Dogs with a urine protein:creatinine (UPC) ratio of >0.5, a baseline cortisol < 2 ug/dL, and a post- prandial bile acids of > 30 uM will be excluded from the study. This will eliminate dogs with protein loss through the kidneys, abnormal production of protein from the liver, or Addison’s disease. These tests can be performed at Tufts.

    All dogs will have an abdominal ultrasound and those with signs of intestinal or extra-intestinal masses will be excluded.

    Yorkshire Terriers, Soft-Coated Wheaten Terriers, and Boxers will be excluded, as these dogs have unique IBD features that respond differently from the general population of dogs.

    Dogs with congestive heart failure, Cushing’s disease, diabetes mellitus, or cancer will also be excluded.

    Client Benefits:

    Expenses associated with giving the injection of stem cells and in evaluating your dog after the injection will be covered. Some initial testing, recheck examinations, and follow-up blood work will be covered. Your pet’s participation will also allow us to gain valuable information which will help in the management and treatment of other dogs with this condition.

     

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

  • Sponsor:  Private Foundation

    CSRC Protocol #: 027-14

    Status:  Fully enrolled

    Description:

    Currently, no medical treatments have been shown to delay the progression of chronic valvular disease (CVD) in dogs, which is a very common heart disease in dogs. In this disease, heart valves become thickened and can no longer keep blood from leaking backwards, leading to fluid accumulation in the lungs (congestive heart failure, CHF). Surgical repair of the valves has shown potential in reversing some changes from the heart disease and prolonging survival time, but this remains a relatively high-risk surgery that very few veterinary hospitals are capable of performing. The cost of the procedure is also financially prohibitive to most dog owners.

    If we can show that mesenchymal stem cell (MSC) treatment is not only safe but can delay the progression of CVD in dogs, this would be the first non-surgical treatment option available to our canine patients. Our results would also have particular relevance for those human patients who cannot undergo valve repair surgery due to unacceptable anesthetic or surgical risks.

    We hypothesize that MSC therapy is safe when administered intravenously (IV) to dogs in CHF, and MSC therapy will result in improved cardiac function as assessed by echocardiography, cardiac biomarkers, or the quality of life of the patient.

    Inclusion/Exclusion Criteria:                                                                      

    A total of 10 client-owned dogs of any sex or age with active CHF secondary to CVD to the Tufts Foster Hospital for Small Animals will be recruited for this clinical trial. Congestive heart failure will be confirmed on chest x-rays to verify the presence of pulmonary edema (fluid in the lungs).

    Dogs with chronic kidney disease, liver disease, uncontrolled hypothyroidism, cancer, high blood pressure, active infection, metabolic disorders, and autoimmune disease will be excluded from the study.

    Client Benefits:

    The study will cover all of the costs associated with echocardiograms, chest x-rays, bloodwork analysis, blood pressures, ECG monitoring, and recheck exam fees. It will not cover the initial hospitalization cost for congestive heart failure stabilization. It will also not cover any medication costs or costs related to disease of other organ systems. Your pet’s participation will allow us to gain information which will help in the treatment of other dogs with this CVD and CHF. You understand that your animal’s participation in this study may not alleviate or cure his/her ailment.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

  • Sponsor:  Private Foundation

    CSRC Protocol #: 029-14

    Status:  Currently enrolling

    Description:

    Cardiomyopathy is a common affliction of the Boxer breed that is manifested by serious ventricular arrhythmias, dilation and reduced vigor of contraction of the heart, or both. The arrhythmic form of the disease bears a striking resemblance to arrhythmogenic right ventricular cardiomyopathy (ARVC) in people, an important cause of sudden cardiac death in young human athletes that is characterized by replacement of the normal heart muscle by fat, scar tissue, and inflammation.

    Current treatment strategies focus on controlling symptomatic arrhythmias, however no medical treatment has been shown to prevent sudden cardiac death. Current therapies also fail to address the underlying structural changes in the heart muscle that inexorably progress, resulting in worsening arrhythmia, cardiac dilation and, in some patients congestive heart failure.

    Mesenchymal stem cells (MSCs) exert anti-inflammatory and anti-fibrotic effects that may prove useful in attenuating the inflammation and remodeling of the heart muscle that characterizes the disease, in turn improving arrhythmia frequency and potentially quality of life or survival times of dogs with ARVC. The major goal of this study is to evaluate preliminary safety of intravenous administration of MSCs in Boxers with ARVC, and to assess their effect on arrhythmia frequency, improving cardiac structural abnormalities, or prolonging survival in affected animals by reducing inflammation or deposition of scar tissue in the heart.

    Inclusion/Exclusion Criteria: 

    A total of 12 client-owned Boxers of any sex or age with cardiomyopathy will be enrolled in this study. Dogs with advanced congestive heart failure, clinically significant congenital heart disease, kidney or liver disease, cancer, active infection, or autoimmune disease will be excluded from the study.

    Client Benefits:

    The study will cover the costs for your dog’s bloodwork, echocardiogram, blood pressure measurement, ECG and Holter monitoring, 4 hours of observation and continuous ECG monitoring following the injection, and recheck visits during the 6 month study period. The study will also cover up to $500 of any costs incurred due to complications from the study; it will not cover any other medication or hospitalization costs. Your pet’s participation will allow us to gain information which will help in the treatment of Boxers and potentially people with this condition. You understand that your animal’s participation in this study may not alleviate or cure his/her ailment

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

  • Status:  Currently enrolling

    Description:

    Lymphoma is a common cancer in dogs that can be treated with good success, but can rarely be cured. We are trying to develop new ways to prevent, diagnose, and treat lymphoma in dogs. To do this, we plan to study the molecular and cellular biology of canine lymphoma in the laboratory. For these studies, we need to collect small amounts of tissue from a lymph node affected by lymphoma.

    Our goal is to collect canine lymph node, both normal and tumor-bearing (lymphoma) from dogs that present to the Foster Hospital For Small Animals for in vitro investigations of the biology and treatment of this disease. Samples will be collected either via post-mortem collection (normal or lymphoma), at biopsy (lymphoma), or using a fine needle aspirate (lymphoma).

    Inclusion/Exclusion Criteria:                                             

    Normal Lymph nodes:

    Inclusion -

    1. Dogs that are euthanized at the FHSA and the body is available for donation or necropsy.

    Exclusion –

    1. Dogs with metastatic cancer, systemic infectious or inflammatory disease will be excluded.

    Lymphoma:

    Inclusion -

    1. Any dog with newly diagnosed, suspected, or relapsed lymphoma.

    2. The owner consents to sample collection.

    Exclusion (For premortem sample collection) –

    1. Dog objects strongly to FNA or restraint and will not be sedated for other procedures.

    2. Concern for coagulopathy based on:

    a) Physical or historical evidence of petechia, unexplained bleeding or hematomas.

    b) Laboratory or historical evidence increased risk for hemorrhage including thrombocytopenia < 50,000/ul

    Client Benefits:

    There is no monetary compensation for participating in the study nor is there any charge associated with the procedures. The most important benefit to participation is that these studies may help dogs in the future by allowing us to find better ways to prevent, diagnose and treat lymphoma.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

  • Status:  Currently enrolling

    Description:                                                                                                                                                                                The purpose of this study is to better understand what causes gastric dilatation and volvulus (GDV) in dogs. GDV, or bloat, is a common condition in large and giant breed dogs. Due to the importance of GDV in many dog breeds, several large previous studies have investigated potential risk factors for the development of GDV.It is known that there is no single cause for GDV, rather its occurrence is multifactorial, with both genetic and environmental factors contributing. As well as a genetic analysis we want to see if dogs with GDV have different types or amounts of proteins, hormones and other molecules in their blood and tissue, or different bacteria in their gastrointestinal tract.

    We will enroll dogs in five groups:

    1. Dogs with acute GDV
    2. Dogs with chronic bloat and/or gastric instability
    3. Dogs with acute gastric outflow or small intestinal obstruction secondary to foreign material
    4. Healthy control dogs
    5. Euthanized control dogs; and
    6. Euthanized dogs with GDV or gastrointestinal foreign body obstruction

    Inclusion/Exclusion Criteria:

    Group a)  Dogs with Acute GDV

    Inclusion criteria:  Dogs with GDV confirmed via a right lateral abdominal radiograph

    Exclusion criteria:  none

    Group b)  Dogs with chronic bloat

    Inclusion criteria:  Clinical signs consistent with chronic bloat

    Exclusion criteria:  GDV at any time

    Group c) Dogs with acute GI obstruction secondary to foreign material

    Inclusion criteria:  Dogs with GI obstruction secondary to foreign material that require exploratory laparotomy.

    Exclusion criteria:  History of GDV. GI perforation.,  Non-obstructive foreign body that does not require surgery

    Group d) Healthy control dogs

    Inclusion criteria:  Healthy

    Exclusion criteria:  History of GDV

    Group e) Euthanized control dogs

    Inclusion criteria:  Euthanized donated dogs

    Exclusion criteria:  History of GDV

    Group f) Euthanized dogs with GDV or GI foreign body obstruction

    Inclusion criteria:  Dogs that will be euthanized after a diagnosis of GDV confirmed via a right lateral abdominal radiograph, or GI obstruction secondary to foreign material confirmed via abdominal radiographs or ultrasound.

    Exclusion criteria: Surgical treatment of GDV or GI obstruction

    Client Benefits:

    This study will not cover any of the costs associated with treating your dog; although all study related sample collection and analysis is covered by the study. As such, the cost of treatment is the same regardless of whether your dog is enrolled in the study. Your dog’s participation will allow us to gain information which will help us to develop a better understanding of why some large and giant breed dogs develop GDV.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu

     

     

  • Sponsor: Private Foundation

    CSRC Protocol #: 007.15

    Status:  Currently enrolling

    Description:

    The goal of this study is to develop a new treatment for perianal fistulas in dogs.  The current treatments for this severe condition (steroids and cyclosporine) are ineffective in a high percentage of patients and the disease relapses frequently.  Also, cyclosporine is expensive and has many side effects, so a major goal is to develop a therapy which reduces the need for immunosuppressive agents, such as cyclosporine. Previous trials using intralesional injections of stem cells have shown very encouraging results.

    Inclusion Criteria:                               

    • Adult dogs, any breed and either gender, with a clinical diagnosis of anal fistulas (presence of chronic peri-anal fistula(s) with clinical signs of tenesmus, dyschezia)and present with partial or complete relapse from cyclosporine A therapy
    • Age range 1-12 years
    • Weight range 2-100 kg

     

    Exclusion Criteria:

    • Dogs younger than 1 year or older than 12 years
    • Other severe diseases ( severe osteoarthritis, cardiac disease, neoplasia, skin disease)
    • Dogs that have had surgery (cryosurgery, anal sac resection, tail amputation) to treat the anal fistulas

     

    Client Benefits:

    The study will cover all the costs of the examinations (once your dog is found eligible) and stem cell treatments including sedation.  The study will provide $300 to participants toward purchase of cyclosporine during the 1 year study.

    Contact information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu

  • Sponsor: Private Foundation

    IACUC protocol#: G2015-58                                                                                                                                 Status:  Currently enrolling

    Description:

    The goal of this study is to compare plasma biomarkers in the form of extracellular RNA in dogs with mitral valve disease presenting with versus without congestive heart failure.

    This study will be an important step towards making exosome analysis a useful and readily available tool for evaluating the progression, the molecular basis for remodeling, and development of specific therapies for mitral valve disease.

    Inclusion/exclusion criteria:

    All dogs should be over eight years of age in order to control for age related differences.

    Healthy: for controls the dogs will be defined as a healthy animal with a normal physical exam, normal CBC/chemistry panel/UA and no evidence of a heart murmur as documented by a veterinarian

    There will be four populations that will be included in this study:

    • Group 1: Healthy dogs with no cardiac disease
    • Group 2: Dogs with mitral valve disease not in congestive heart failure.
    • Group 3: Dogs with mitral valve disease in congestive heart failure.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

  • Sponsor: Private Foundation                                                                                                                   CSRC Protocol#: 002.15

    Status: Currently enrolling

    Description:

    Cardiomyopathy is a common affliction of Boxer dogs that is manifested by serious ventricular arrhythmias, cardiac dilation and reduced pump function, or both. The arrhythmic form of the disease bears a striking resemblance to arrhythmogenic right ventricular cardiomyopathy (ARVC) in people, an important cause of sudden cardiac death in young human athletes that is characterized by replacement of the normal heart muscle by fat, scar tissue, and inflammation. ARVC can be challenging to diagnose.  Genetic testing is imperfect and ARVC screening usually entails a combination of family history, genetic testing, electrocardiographic and echocardiographic findings.

    The development of blood-based cardiac biomarkers has revolutionized the way in which we screen for certain types of heart disease. MicroRNAs (miRNAs) are small non-coding RNAs that play important roles in modifying gene expression. MiRNA gene expression patterns are altered in several types of cardiac disease in people and miRNA-based therapeutics are an area of active research. MiRNAs are uniquely suited to serve both as non-invasive biomarkers of disease and also potential therapeutic targets.

    The goals of this pilot study are twofold: 1) to determine the feasibility of measurement of miRNAs from circulating exosomes in canine peripheral blood samples; and 2) to compare expression patterns of candidate miRNAs between normal Boxers and Boxers affected with ARVC. We hypothesize that measurement of miRNAs from within exosomes circulating in canine plasma will be feasible, miRNA will be enriched in the exosome rather than the non-exosomal fractions, and furthermore that Boxers affected with ARVC will have altered miRNA expression patterns relative to age- and breed-matched healthy controls.

    16 Boxers – 8 Normal, 8 with ARVC

    Inclusion Criteria:

    Normal boxers:           > 5 years of age

    < 50 VPCs/24 hr on Holter monitor

    Boxers with ARVC:      Any age with ≥500 VPC/24 hr on a Holter monitor or

    Ventricular ectopy sufficiently severe to begin antiarrhythmic therapy

    Exclusion criteria:

    Dogs with ACVIM Class C or D congestive heart failure, and those with clinically significant congenital heart disease, advanced renal or hepatic disease, diabetes mellitus, malignant neoplasia, active infection, or autoimmune disease will be excluded from the study.

    Administration of antiarrhythmics or other cardiac medications deemed necessary by each dog’s clinical condition will not preclude enrollment in the study.

    Client Benefits:

    The study will cover the costs for your dog’s bloodwork, echocardiogram, ECG, and Holter monitor today. Your pet’s participation will also allow us to gain information which will help in the diagnosis and treatment of other Boxers with this condition. You understand that your animal’s participation in this study may not alleviate or cure his/her ailment.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu

  • Status: Currently enrolling

    Description:

    The primary goal of this study is to evaluate the efficacy of diphenoxylate hydrochloride plus atropine sulfate (Lomotil) as treatment for diarrhea in dogs receiving treatment with toceranib phosphate (Palladia) for cancer. Toceranib is an increasingly commonly used drug in veterinary oncology since it was approved by the Food and Drug Administration in 2009. Diarrhea is often a dose-limiting side effect and negatively impacts patient quality of life.

    To date, there are no standard or evidence-based protocols for supportive care to mitigate the adverse events while patients receive toceranib.  Toceranib is being used with increasing frequency in veterinary oncology, but this treatment is associated with a relatively high rate of adverse events. The most common adverse event described is diarrhea, which can lead to drug holidays and dose reductions. If diphenoxylate + atropine is effective at controlling diarrhea, it is anticipated that more dogs would be able to receive appropriate doses that reliably achieve therapeutic drug levels with fewer drug holidays, thereby enhancing tumor control while preserving good quality of life

    Inclusion Criteria:

    Canine patients presenting the Foster Hospital of Small Animals who will be prescribed toceranib at a target dose.

    Exclusion Criteria:

    • History of chronic diarrhea
    • Gastrointestinal upset (nausea, vomiting, diarrhea, inappetence) within three days prior to the start of toceranib
    • Patients may not have received any medication for nausea or diarrhea within 7 days of starting toceranib
    • Patients may be on concurrent medications associated with gastrointestinal toxicity (prednisone, NSAIDs, cyclophosphamide) as long as they have been on the medication for at least two weeks without gastrointestinal upset.
    • Patients receiving monoamine oxidase inhibitors will be excluded due to possible drug interactions
    • Creatinine above the upper limit of the normal reference range
    •  Alanine aminotransferase (ALT) >3 times the upper limit of normal, icterus or increased bile acids
    • Hypoadrenocorticism.

    Client Benefits:

    The study will cover the cost of the anti-diarrhea medication and the examination fee at the 4-week recheck visit. You are responsible for the cost of the initial consultation, 2-week recheck examination, all blood tests and Palladia. Your pet’s participation will also allow us to gain information which will help in the management of other dogs with similar disease.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu

  • Sponsor: Private Foundation

    CSRC Protocol #: 009.15

    Status:  Currently enrolling

    Description:                               

    Atopic dermatitis (AD) affects approximately 10% of the canine population globally and is likely the most prevalent skin disease in the dog requiring medical intervention. Current treatment options for canines include antihistamines, corticosteroids, cyclosporine A, oclacitinib, and allergen-specific immunotherapy (ASIT) administered subcutaneously or sublingually, as well as adjunctive treatments such as topical and systemic antimicrobial therapy. Avoidance of implicated allergens is impractical or impossible in most cases. The problem with the above treatment options is that they are not entirely reliable therapeutic modalities, have potential for adverse reactions, or they come with significant financial burden. There is a great need for finding a novel, safe, and effective treatment for the management of canine AD.

    Multipotent mesenchymal stem cells (MSCs) have been extensively evaluated in human medicine for their clinical applications in the repair of damaged tissues and in the treatment of chronic, degenerative inflammatory diseases because of their diverse wound healing and anti-inflammatory properties.

    Our primary goal is to investigate the safety and biological activity of canine placental (fetal) derived MSCs in alleviating the clinical signs associated with canine atopic dermatitis. Our secondary goal is to investigate the feasibility of this protocol for future applications in larger scale randomized controlled double-blinded clinical trials.

    Inclusion Criteria:

    1. Males or females, neutered or intact, greater than one year of age
    2. Have a minimum body weight of 5 kg
    3. Have a diagnosis of AD made based on history, clinical signs, exclusion of all other pruritic disease, meeting the de facto established criteria by Willemse and Prelaud. Cutaneous adverse food reaction will have been ruled out using a novel protein elimination diet trial for 8 weeks with no subsequent change in pruritus level following a provocation trial.
    4. Must be on and remain on ectoparasite preventatives for the duration of the trial.

    Exclusion Criteria:

    1. Dogs with other systemic diseases (severe osteoarthritis, cardiac disease, neoplasia, skin diseases) apart from atopic dermatitis will be excluded
    2. Inadequately treated skin infection

    Client Benefits:

    The study will cover all of the costs associated with this study. If an adverse event, such as an allergic reaction should occur, the study would cover the cost of treatment up to a limit of $500; adverse reactions or other complications will be managed by our ICU staff.

    Your pet’s participation will allow us to gain information, which will help in the diagnosis/management/treatment of other dogs/cats/horses/others with this condition. You understand that your animal’s participation in this study may not alleviate or cure his/her ailment.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu

     

     

  • Status:  Currently enrolling

    Description:

    The success of cardiopulmonary resuscitation (CPR) is very low, in veterinary (as well as human) patients. Even after successful return to spontaneous circulation, sequela to CPR include repeated cardiac arrest, brain disease, and multi-organ system failure. Low oxygen levels to the brain is the major factor contributing to these poor outcomes. There is a critical gap in our understanding of the physiology and prognosis after CPR, which has led to failure to substantially improve our success in dealing with this problem.

    An important goal of this study is to understand how chemicals called nucleic acids (RNA) are altered in post-CPR canine patients. The study will focus on very small RNA (miRNA). The specific objective of this study is to understand which miRNA are released into the circulation of canine patients after cardiopulmonary resuscitation (CPR) versus non-CPR patients hospitalized in the ICU for other reasons.

    There is tremendous potential value in identifying circulating miRNA after CPR. First, miRNA may assist in predicting outcome (prognosticating) in individual patients in the future. Second, miRNAreleased into the circulation are indicators of major epigenetic disturbances as a consequence of hypoxia-ischemia.    Knowledge of these miRNA may lead to the design of novel therapies to counteract these effects, for example employing stem cells that release mitigating miRNA.

    Inclusion Criteria:

    Group 1:  Six dogs that have undergone CPR according to standard protocols in the TCSVM emergency room and have returned to spontaneous circulation for a minimum of 1 hr.

    Group 2:  Six dogs hospitalized in the ICU that have not experienced CPR or significant hypoxemia or ischemia (e.g. GDV, hemorrhage, stroke) will be selected for sampling at the same time (AM vs. PM). Dogs will be similar age and gender as post-CPR patient.

    Any breed is acceptable.

    Exclusion Criteria:

    • Dogs < 10 kg
    • Dogs with prior hypoxemia insult (prior arrest or CPR, GDV, stroke, hemorrhagic shock, congestive heart failure, etc).
    • Dogs with a diagnosis of cancer
    • Dogs with hemolytic disease
    • Dogs for which blood sampling is contraindicated (recent fluid/colloid resuscitation)

     

    Client Benefits:

    The study will cover the cost of a blood panel (NOVA) at the same time the sample is being collected; this is testing that is normally performed every few hours during recovery from CPR, it is also testing that is normally performed in sick dogs. Your pet’s participation will also allow us to gain information which will help in the treatment of other dogs with this condition. You understand that your animal’s participation in this study may not alleviate or cure his/her ailment

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu

     

  • Sponsor: Private Foundation

    CSRC Protocol #: 117.15

    Enrollment: Currently enrolling

    Description:

    Dogs presenting with acute, concussive disk herniations share many similarities with human spinal cord injury patients. The prognosis for return to normal function is very guarded in dogs with acute onset of paraplegia and loss of pain perception in hind legs. The likelihood to regain ambulatory status is within the range of 43-69%. Fecal incontinence was observed in 41% and urinary incontinence in 32% of dogs regaining pain perception and ambulatory function. In dogs which fail to regain pain perception and ambulatory function after surgery, fecal and urinary incontinence will persist and frequent urinary tract infections are common. In addition, in some dogs this dysfunction can progress to the level of ascending urinary tract infection and sepsis.    New therapies are needed to improve these outcome.

    We propose to transplant allogeneic Wharton’s Jelly (umbilical cord matrix) mesenchymal stem cells (WJ-MSC) into the spinal cord of dogs admitted to the Foster Hospital at Cummings Veterinary Medical Center at Tufts University because of severe spinal cord injury secondary to intervertebral disc herniation/compression in order to study their potential as neuroprotective and regenerative agents.

    Our hypothesis is that chondrodystrophic dogs with an acute onset of paraplegia and loss of pain perception caudal to a thoracolumbar disk extrusion treated with decompressive surgery and subdural allogeneic WJ-MSC will have a significantly higher likelihood of a functional recovery than dogs treated with decompressive surgery alone.

    In this prospective study, paraplegic dogs with absent pain perception will be randomly assigned to WJ-MSC (in Cryostor) plus surgery or vehicle (Cryostor) plus surgery. Parameters of interest include time to return of pain perception, motor function, ambulation and urinary/fecal continence. A successful outcome will be defined as return to ambulatory function, normal pain perception caudal to the lesion and full urinary and fecal continence within 3 months post-surgery.

    A positive functional outcome as a result of stem cell transplantation would be a tremendous benefit and step forward for dogs being affected with concussive disk herniations. Determining such efficacy, along with an assessment of any related complications, would provide an ideal naturally occurring disease model in dogs could also be utilized in human therapeutics of spinal cord injury.

    Inclusion Criteria:

    Dogs of any age, sex weighing less than 25 kg with the following:

    ° Complete medical history

    ° Owner consent for inclusion into study

    ° Paraplegia with absent pain perception in hind legs and tail at admission

    ° Extradural compression between T3 – L3 diagnosed with CT or MRI

    ° Acute disk extrusion confirmed at surgery

    ° Follow up performed at Cummings School of Veterinary Medicine at Tufts University by neurology service

    Exclusion criteria:

    ° Unable to confirm disk extrusion intraoperatively

    ° Concurrent disease that could interfere with neurologic recovery

    ° Inability to obtain in-hospital follow-up performed at Tufts University by the neurology service

    ° No owner consent

    Client benefits:

    The study will cover all of the costs of stem cells treatment and follow-up appointments up to 3 months after the surgery, as well as contribute $1100 towards the cost of surgery. Your pet’s participation will also allow us to gain information which will help in the diagnosis/management/treatment of other dogs with this condition. You understand that your animal’s participation in this study may not alleviate or cure his/her ailment.

    Contact information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

  • Status:  Currently enrolling

    Description:

    This clinical trial led by the National Cancer Institute (NCI) and sponsored by the Morris Animal Foundation seeks to evaluate in dogs with osteosarcoma the safety and effectiveness of Standard of Care therapy, with or without adjuvant rapamycin administration. Standard of Care is defined as definitive surgery, being amputation of the affected limb, followed by 4 doses of intravenous carboplatin chemotherapy given on a q21 day schedule. Carboplatin has been safely and effectively used to treat appendicular osteosarcoma in dogs for > 20 years, but the potential for unforeseen potentially life-threatening side effects from surgery, chemotherapy, and/or progressive cancer does exist. ALL dogs enrolled onto study will receive Standard of Care therapy; however, through a randomization process, some dogs entered into study will also receive additional therapy with oral rapamycin.

    Rapamycin is a drug currently approved for immunosuppression during preparatory and maintenance regimens for organ and bone marrow transplant in human patients. Early work with rapamycin suggests that this agent might also have anti-cancer properties by inhibiting (reducing the effects of) an important pathway in cancer progression known as mTOR. Preclinical studies of rapamycin in mice, as well as recent data using analogous drugs in human patients (rapalogs), suggest that mTOR blockade might be effective in the treatment of several cancers. In a recently completed study of rapamycin in dogs with cancer, a dose and schedule for rapamycin administration have been defined which appears to be safe and tolerable by most dogs.

    Within this study, dogs will undergo surgical amputation of the affected limb. Dogs will return to Cummings Veterinary Medical Center every 3 weeks for 15 weeks for evaluation. On weeks 3, 6, 9 and 12, dogs will receive treatment carboplatin chemotherapy. After 15 weeks of Standard of Care, based upon initial study randomization, dogs will either receive oral rapamycin on a 4 day on/3 day off schedule for 4 months or will not be treated with any additional medications and simply be monitored every 8 weeks.

    Eligibility Criteria:          

    1. Histologically or cytologically (inclusive of alkaline phosphatase positivity) confirmed osteosarcoma
    2. Measurable disease that is amenable to surgical removal via amputation (No evidence of metastasis based upon physical exam, chest x-rays, and abdominal ultrasound).
    3. Favorable performance status: Grade 0 or 1 (modified ECOG [Eastern Cooperative Oncology Group] criteria) - Briefly, Grade 0 means that the animal’s activity level is completely normal; Grade 1 allows for mild lethargy but the animal is still able to perform all “activities of daily living.”
    4. ONLY newly diagnosed dogs are eligible with no prior therapy (conventional or metronomic chemotherapy, ionizing radiation, bisphosphonates) for osteosarcoma
    5. Dogs receiving analgesics including NSAIDs, gabapentin, tramadol, or other will be eligible for study inclusion
    6. Informed owner consent for trial (approved by CSRC/IACUC) - Client’s informed consent includes permission for dogs to undergo full post-mortem examination (necropsy) if the dog dies while on study

    Exclusion Criteria:

    1. Weight < 25 kg (55 pounds)
    2. Dogs without measurable disease (appendicular osteosarcoma) at presentation to Tufts
    3. ANY prior therapy for osteosarcoma (conventional or metronomic chemotherapy, ionizing radiation, bisphosphonates)
    4. Concurrent medications deemed incongruent with this study; to be determined by NCI COTC investigators.
    5. Significant co-morbid illness, which includes but is not limited to renal or hepatic failure, history of congestive heart failure or clinical coagulopathy
    6. Creatinine > 3.0 mg/dL
    7. Bilirubin > 2.0 mg/dL or elevated bile acids
    8. HCT < 25%, platelets < 150,000 cells/ul
    9. Any hematologic/biochemical abnormality > grade 1 ( According to the Veterinary Cooperative Oncology Group – Common Terminology Criteria for Adverse Events [VCOG-CTCAE] v1.1 – which appears in Appendix II in the COTC protocol)

    Client Benefits 

    Costs associated with this study (including carboplatin and rapamycin administration and study-related evaluations will be covered by the study. In addition, $1,000 will be provided towards the cost of surgical amputation

    Contact Information:

    For questions regarding the clinical trial, please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

     

  • Status:  Fully enrolled

    Description:

    Atopic dermatitis (AD) is a genetically predisposed inflammatory skin condition affecting approximately 10% of dogs globally and is probably the most prevalent skin disease in canines.1 Affected dogs manifest with itchy skin and ears and secondary infections.

    Current treatment options include antihistamines, corticosteroids, cyclosporine, oclacitinib, and allergen-specific immunotherapy (ASIT), as well as adjunctive topical and antimicrobial therapy.

    Antihistamines are effective in ≤25% of dogs. Corticosteroids are extremely efficacious; however, adverse reactions are common, thus long-term use is strongly discouraged. Cyclosporine is effective in many dogs with few serious adverse effects, but cost can be a limitation in large breed dogs. Oclacitinib has been shown to have good efficacy, but long term side effects have not been studied, nor is the drug available currently in a consistent basis due to manufacturing issues. ASIT appears as the only treatment that is able to induce a clinical cure. However, the percentage of atopic dogs that respond to this treatment is only 60-70% and in many, the response is only partial.4-9

    It has been proposed that subcutaneous ASIT is less than ideal because of the limited ability of the skin to stimulate the immune system. This study proposes an alternative route of administration for ASIT. Direct administration of allergens into a peripheral lymph node may be more effective in stimulating an immunologic reaction thereby increasing the response rate and potentially the cure rate for canine atopic dermatitis.

    Inclusion criteria:

    1. Males or females, neutered or intact, greater than one year of age

    2. Have a minimum body weight of 10.0 kg

    3. Have a diagnosis of AD made based on history, clinical signs, exclusion of all other pruritic disease, meeting the de facto established criteria by Willemse and Prelaud. Cutaneous adverse food reaction will have been ruled out using a novel protein elimination diet trial for 8 weeks with no subsequent change in pruritus level following a provocation trial.

    4. Dogs with secondary superficial infections such as Malassezia dermatitis and bacterial folliculitis will be allowed and will be treated with systemic and topical antimicrobial therapy as needed

    Exclusion criteria:

    1. Dogs with other systemic diseases (severe osteoarthritis, cardiac disease, neoplasia, skin diseases) apart from atopic dermatitis will be excluded.

    2. Current immunosuppressive therapy

    Client Benefits:

    The study will cover all of the costs of this study with the exemption of complications in which you will remain financially liable for the cost of such care. Your pet’s participation will also allow us to gain information which will help in the treatment of other dogs with atopic dermatitis. You understand that your animal’s participation in this study may not alleviate or cure his/her ailment.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu

     

     

  • Tufts researchers are studying what pet owners think about pet health and treatment. Will you take an 8 minute survey to help us provide better care for pets in the future? 

     

    Survey Link: http://bit.ly/21UWPa0

     

     

     

  • Status:  Currently enrolling

    Description

    Bisphosphonates, such as pamidronate and more recently zoledronate, are commonly used for palliation of pain related to malignant osteolysis. Acute systemic inflammatory responses, cardiac arrhythmias, ocular toxicity and significant elevations in pro-inflammatory cytokines have been observed in association with bisphosphonate therapy in humans, although the frequency is uncertain. The primary objective of this study is to investigate if there is an increase in biomarkers of inflammation and myocardial injury after zoledronate administration in dogs with malignant osteolysis. A secondary objective is to assess body temperature and to determine if there is an association between zoledronic acid-induced rise in temperature and elevation in inflammatory biomarkers.

    Inclusion Criteria

    • All dogs must be at least one year old on Day 0.
    • All dogs must weigh at least 5kg on Day 0.
    • All dogs must have complete baseline cancer staging involving physical exam, chemistry profile and urinalysis prior to enrollment.
    • Dogs must have adequate organ function as indicated by standard laboratory tests: hematology (CBC), clinical chemistry and urinalysis.
    • All dogs must have either radiographic or advanced imaging to confirm the presence of a lytic bone lesion.
    • All dogs must be intended to receive intravenous zoledronate to alleviate associated bone pain as part of their therapeutic plan.

     Exclusion Criteria

    • Dogs that had received prior bisphosphonate (pamidronate or zoledronate) administration.
    • Evidence of severe kidney dysfunction.
    • Dogs that are receiving corticosteroids for at least 7 days prior to enrollment.

    Client Benefits

    The study will cover the costs associated with one administration of one dose of zoledronate, three CBCs, and the costs of blood tests involved in the study. This amounts to a total financial benefit of approximately $550.  The client will be responsible for all other costs associated with the cancer staging (initial consult, chemistry profile, urinalysis, and radiographic or other advanced imaging evidence of a lytic bone lesion) as well as any additional treatments with zoledronate or other cancer therapy during and after completion of the study. Each patient’s participation will allow us to gain information which will help in the side effect management of future dogs undergoing treatment with zoledronate.

    Have a case?  

    Contact Drs. Michele Keyerleber or Molly Holmes at (508) 887-4682, Michele.Keyerleber@tufts.edu or Molly.Holmes@tufts.edu            

  • Status:  Currently enrolling

    Description:

    The purpose of the study is to investigate ways to monitor dogs that have been diagnosed with chronic inflammation in their liver so called chronic hepatitis in dogs. We are performing this study to evaluate whether these blood tests correlate with the severity of the dog’s liver disease.

    Inclusion Criteria:

    • Dogs weighing greater than 6 kg (13 lbs)
    • Dogs with histologically confirmed chronic hepatitis

    Exclusion Criteria:

    • history of use of corticosteroids, ursodeoxycholate, NSAIDs, omega-3 or vitamin D supplementation within 2 weeks of enrollment or the use of DDAVP within 24 hours
    • degenerative mitral valve disease, renal disease (Creat >2.0 mg/dL), concurrent active infection, neoplasia, IBD, immune mediated hemolytic anema, pnacreatitis or immune mediated polyarthropathy

    Client Benefits:

    The study will cover the costs of the vitamin D, CRP and von Willebrand factors as well as a complete blood count and serum chemistry at the first recheck appointment.

    Contact information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

     

     

  • Status:  Currently enrolling unaffected dogs only

    Description:

    Degenerative mitral valve disease (DMVD) is the most common form of heart disease in the dog, accounting for more than 70% of cardiac disease and affecting at least 11% of all dogs (and up to 90% of certain breeds, such as the Cavalier King Charles Spaniel). Some breeds of dogs are genetically predisposed to DMVD, but genetics do not completely explain the disease and its progression. Research on factors that may increase the risk for heart disease in genetically predisposed individuals is underway in both people and companion animals, and includes factors such as diet, exercise, and hormones. This is particularly important in people where heart disease is a leading cause of death.

    Recently, a compound called trimethylamine N-oxide (TMAO) has received a great deal of attention due to its association with heart disease in people. Trimethylamine N-oxide is produced when the bacteria in people's intestines metabolize nutrients in the diet, such as choline and L-carnitine. High levels of TMAO, choline, and L-carnitine in the blood have all been shown to be associated with increased risk of heart disease and death from heart disease in people.

    Based on the recent research on TMAO in people, the investigators have begun evaluating its role in canine heart disease.  It is unknown if blood levels of TMAO, choline, or L-carnitine are different in dogs with DMVD compared to healthy controls. Nor is it known if these levels differ in dogs with DMVD with and without congestive heart failure (CHF). Therefore, the goal of the proposed study is to identify whether the higher blood levels of TMAO, choline, and L-carnitine found in people with heart disease also occur in dogs with DMVD, and if the levels in dogs with CHF are higher than in those without CHF.

    Inclusion Criteria:

    • Dogs with asymptomatic DMVD
    • Dogs with DMVD and CHF
    • Age- and breed-matched healthy control dogs.

    Exclusion Criteria:

    • Dogs currently receiving other non-cardiac medications (except monthly parasite preventative medication, which will be allowed),
    • Dietary supplements containing carnitine, choline, precursors of carnitine or choline, or supplements that might modify gut microflora (e.g., probiotics) will be excluded.
    • Dogs in the control group and in the asymptomatic DMVD group with a serum creatinine >2.1 mg/dL will be excluded
    • Dogs in the DMVD CHF group with a serum creatinine > 2.4 mg/dL will be excluded.
    • Dogs with other major diseases (e.g., cancer, diabetes mellitus) will also be excluded.

    Client Benefits:

    The study will cover the costs of hospital registration, a cardiology consultation or appointment, and echocardiogram, blood testing (complete blood count, biochemistry profile, and measurement of TMAO, choline, and carnitine). Your dog's participation will also allow us to gain information about the cause of this disease which will help in the treatment of other dogs with this condition. You understand that your dog's participation in this study may not alleviate or cure his or her ailment.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

     

     

     

     

     

     

     

  • Sponsor:  Private Foundation

    IACUC protocol # G2016-31

    Status:  Currently enrolling

    Description:

    Dry eye (keratoconjunctivitis sicca =‘KCS’) is a serious condition in dogs, affecting up to 20% or more of some breeds.   The basis for dry eye is unknown, although the gland (‘lacrimal gland’) that keeps the eye lubricated is badly damaged by cells of the body that maintain our defenses (‘immune cells’).    Thus it is called an ‘auto-immune’ disease.   A human disease called Sjogren’s Disease has a similar appearance, thus dry eye might be a model for human Sjogren’s Disease.  The specific objective of this study is to improve our understanding of the cause of dry eye, by analyzing blood and saliva which contain clues (i.e., biomarkers, specifically in the form of ‘microRNA’) to the origin of the disease.    The hypothesis is that these biomarker miRNA in saliva and blood will shed light on the underlying cause because miRNA control the function of our genes (DNA).    The explicit goal is to find which miRNA differentiate dogs with dry eye from normals.

    Understanding better the underlying cause of dry eye will potentially lead to (1) earlier diagnosis, (2) prediction of the rate of disease progression (prognosis), (3) design of new therapies that specifically address the cause of disease, and (4) evidence that canine dry eye is related to the similar human disease (Sjogren’s Disease).  The primary goal of this current study is to measure biomarkers present within the saliva/blood of canines with naturally occurring dry eye (KCS).

    Inclusion criteria

    A total of 40 dogs will be enrolled in this study, including 20 dogs diagnosed with KCS, and 20 control dogs.

    1. Mature dogs (> 1 yr) of any body weight, breed, or gender
    2. KCS group: diagnosed by principal investigator with KCS based on routine ophthalmologic examination and Schirmer Tear Test (<10 mm/min).
    3. Control group: healthy dogs without a diagnosis of KCS and with a normal Schirmer Tear Test. Control dogs will be matched based on age, and ideally breed, and sex. Control dogs must also lack any signs of illnesses related to the eye, or co-morbidities (cancer, heart disease, kidney disease, liver disease, etc).

    Exclusion criteria

    1. Dogs with neurogenic KCS, diabetic KCS, or radiation induced KCS, or other specific causes of dry eye (i.e. chronic sulpha drug usage).
    2. Dogs which have undergone KCS related surgery.
    3. Dogs with non-KCS ocular or peri-ocular diseases, co-morbidities, cancer
    4. Dogs with severe periodontal disease
    5. Dogs (KCS and control dogs) which have received anti-inflammatory therapies within the past month

    Client Benefits:

    For your participation in this project, we will pay for the costs associated with routine blood work (i.e. complete blood count, serum biochemistry profile, total T4) and urinalysis ($200 dollar value). Your pet’s participation will also allow us to gain valuable information which will help in the diagnosis, management, or treatment of other dogs with this condition. You understand that your animal’s participation in this study will not alleviate or cure his/her ailment.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

     

     

  • Status:  Currently enrolling

    Description

    The goal of this study is to assess the presence and degree of vascular abnormalities which are thought to exist within the eyes of diabetic canines. Diabetes is one of the most common endocrinopathies affecting dogs. In humans, diabetes results in microangiopathies (diabetic iridopathy and retinopathy) which are significant vision threatening sequelae. While noted to occur in diabetic canines, little published information exists regarding its degree and/or severity. This study will perform a diagnostic work up, including a 24 hour blood glucose curve, in addition to, ocular angiography using both sodium fluorescein and indocyanine green, in a total of 8 diabetic canines. Our goal is to document and characterize vasculature changes (vascular leakage, delayed perfusion) which are thought to occur in diabetic dogs and correlate them to disease status and/or duration. Data generated herein, will provide the necessary information for conducting longitudinal studies, correlating the prevalence and severity of these vascular abnormalities to the duration of disease and regulation status. Knowledge regarding the prevalence and severity of these vascular abnormalities could translate into better preventative medicine and/or improved patient outcomes following surgery (i.e. cataract surgery) in our canine patients.

    Inclusion Criteria

    1. New or previously diagnosed canines with diabetes mellitus. A diagnosis of diabetes mellitus is based on a history of polyuria, polydipsia, polyphagia, blood glucose above 250mg/dl, and glucosuria.

    Exclusion Criteria

    1. Diabetic canines exhibiting any signs/symptoms suggestive of concurrent systemic disease(s) will not be considered.  Excluding conditions include diseases that cause insulin resistance such as hyperadrenocorticism and/or those which may be associated with vascular abnormalities (i.e.renal failure, neoplasia, and heart failure)
    • Dogs receiving corticosteroids within the previous 30 days will be excluded.

     Client benefits

    The study will cover the following costs associated with participation in this study: the cost of a complete blood count, serum biochemistry profile, urinalysis and culture. Additionally, costs of conducting a 24 hours blood glucose curve (including hospitalization charges) and a fructosamine level will be covered. For angiographic purposes, canines will be sedated the following day and receive intravenous administration of two commonly employed angiographic dyes. The study will cover the costs associated with conducting ocular angiography.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

  • Status:  Currently enrolling

    Description:

    To determine if losartan, a medication used to reduce protein loss through the kidneys, is broken down and processed differently in dogs with kidney disease compared to healthy dogs.

    To compare the ability of losartan to control protein loss through the kidneys in dogs with protein-losing kidney disease (protein-losing nephropathy, or PLN) with benazepril, one of the medications in the class of medications (angiotensin-converting enzyme inhibitors) that is currently standard therapy for this disease.

    We hypothesize that the processing of losartan in dogs with PLN will be altered compared to the patterns previously established in healthy dogs, and that losartan will be equally or more effective than benazepril at treating PLN.

    This study serves to evaluate losartan, a medication commonly used in human medicine, for its role in helping to treat protein-losing nephropathy, a potentially devastating disease in dogs.  If successful, this may open a new option for treatment of dogs with PLN who don’t respond to standard therapies, such as benazepril.  In addition, the pharmacokinetics of losartan (or any angiotensin-receptor blocker) in dogs with PLN has not been previously evaluated.

    Inclusion Criteria:

    Dogs who have been diagnosed with protein-losing nephropathy (as defined by having a urine protein:creatinine ratio >2.0 with no evidence of non-renal causes of proteinuria).

    Client benefits:

    The direct benefit from this study for your dog is that he or she will receive one of two promising therapies for protein-losing kidney disease with close monitoring of his or her response to therapy.  The direct benefit to you is that the costs of either medication (benazepril or losartan) will be covered for the duration of the study (6 months).  You will be responsible for the costs of the preliminary diagnostic tests (including ultrasound) and the costs of the recheck appointments and urine and blood testing at these rechecks.

    Contact information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

     

  • Status:  Currently enrolling

    Description:

    Portal vein thrombosis during the early postoperative period is a significant cause of death in dogs undergoing splenectomy for splenic mass lesions. Thrombocytosis following splenectomy is common in humans, and the resultant hypercoagulability is a known risk factor for portal vein thrombosis. It is not known whether post-splenectomy thrombocytosis or hypercoagulability develop in dogs. We hypothesize that some dogs undergoing splenectomy for splenic masses develop increases in platelet count and become hypercoagulable during the first 2 weeks after splenectomy. We also hypothesize that postoperative platelet counts will be higher among dogs that present with hemoabdomen than among dogs that do not, because intra-abdominal hemorrhage from a splenic mass may result in a temporary consumptive thrombocytopenia and rebound thrombocytosis

    Inclusion criteria:

    Dogs undergoing splenectomy

    Client benefits:

    The study will cover the costs associated with all blood tests evaluated in the study. These tests may or may not be beneficial in the management of your dog’s condition. Your dog’s doctor may determine that additional blood tests are necessary for diagnosis and treatment; the cost of these diagnostics will not be covered by the study. Your pet’s participation will also allow us to gain information which will help in the management/treatment of other dogs undergoing splenectomies in the future.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

     

     

  • Status:   Currently enrolling

    Description:

    Canine degenerative myelopathy (DM) is an inherited, progressive spinal cord disease, generally noticed after the age of 8 years.  Clinical signs are initially very mild and refer to a thoracolumbar spinal cord disease. Over time the clinical signs progress to lower motor neuron signs in the pelvic limbs, paraplegia, and later loss of motor function including in front legs with brainstem signs in the end stage.  Breed and also owner decision are important factors for survival since many dogs are euthanized when they can no longer walk.   The suspected diagnosis of degenerative myelopathy is established by exclusion of disorders causing similar signs such as chronic disk disease, spinal tumors , degenerative lumbosacral stenosis, hip dysplasia, chronic cruciate ligament disease or neuromuscular disorders.   Effective treatment options are not available.

    Many cases of canine degenerative myelopathy are caused by mutations in the gene encoding superoxide dismutase (SOD1). The purpose of the study is to determine whether a suppression of the activity of the mutant SOD1 gene can stop the progression of the clinical signs. In this study, the gene suppressing compound, is delivered to the spinal cord and brain using a small vector (known as adeno-associated vector or AAVrh10).

    Inclusion Criteria:

    1. Species: canine
    2. Sex: male, castrated male, female , spayed female
    3. Age Range: > 8 years
    4. Weight Range: > 20 kg
    5. Other:
    • Breeds: German shepherd, boxer, welsh corgi
    • History of chronic progressive hind end weakness
    • Ambulatory condition, neurological signs referring to a T3 - L3 localization
    • Only dogs without structural spinal cord lesions such as compressive intervertebral disk disease, spinal tumors, infectious or non-infectious meningomyelitis, malformations and degenerative lumbosacral stenosis will be included. The parameters should be within normal limits for CBC, chemistry profile, chest radiographs and MRI T3 - S1.
    • Only dogs without structural spinal cord disease and a homozygous SOD1 mutation will be enrolled into this study.
    • Signed consent form by owner including that dogs after adeno-associated vector treatment will undergo an autopsy with cremation of the body.

    Exclusion Criteria:

    1.  Dogs with structural spinal cord disease such as such as compressive intervertebral disk disease, spinal tumors, infectious or non-infectious meningomyelitis, malformations and degenerative lumbosacral stenosis will be excluded
    2. Dogs with active hepatitis will be excluded
    3. Dogs who are not homozygous for the SOD1 mutation will be excluded
    4.  We will exclude dogs for whom the owner does not sign a consent form.

    Client Benefits:

    The study will cover all the expenses related to the study and follow-up . This includes additional anesthesia procedures, additional MRI exam to inject the gene suppression compound, CSF analysis, vector treatment, recheck exams, force plate analysis, whole body EMG, motor test conduction of nerves, bloodwork, autopsy and cremation. The initial expenses such as initial neurological examination and intial MRI and anesthesia will not be covered by the study funds. Your pet's participation will also allow us to gain information which will help in the diagnosis and management and treatment of other dogs diagnosed with degenerative myelopathy, a disorder which is currently not treatable. You understand that your animal's participation in this study may not alleviate or cure his/her ailment.

    Contact information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu

     

     

  • Status: Currently enrolling

    Description:

    The goal of this study is to measure the presence of a blood marker, miRNA, in dogs with naturally occurring bone cancer (osteosarcoma) and compare these results to healthy unaffected dogs. We hypothesize that the presence of this biomarker will positively correlate with the presence of tumor and high expression levels may be associated with outcomes of disease-free interval and survival time in dogs with osteosarcoma.  Approximately 10 mls (2 teaspoons) of blood will be collected from your dog’s vein via routine blood sampling. Blood collection ideally will occur both prior to and following removal of your dog’s tumor. This is a safe amount of blood that can be sampled in any dog greater than 5 kilograms.

    Inclusion Criteria:

    Dogs with osteosarcoma weighing 5 kilograms (11 pounds) or greater

    Client Benefits:

    Your pet’s participation will allow us to gain information, which will help in the diagnosis/management/treatment of other dogs with this condition. You understand that your animal’s participation in this study may not alleviate or cure his/her ailment.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

  • Sponsor: Private foundation

    IACUC Protocol # G2016-125

    Status: Currently enrolling

    Description:

    This study has two components;

    1. To examine blood from dogs with skin diseases (including atopic dermatitis, pemphigus foliaceus and perianal fistulas) compared with blood from healthy dogs to identify factors (‘biomarkers’) that may play a role in the disease process.
    2. To develop a blood test for the skin disease (pemphigus foliaceus, or ‘PF’).

    It is hoped this study will enable us to gain a deeper understanding of disease processes with the long term goal of finding alternate approaches to diagnose, monitor, prevent or treat these chronic skin diseases.

    Inclusion Criteria:

    Blood samples from dogs presenting to the Tufts dermatology service with skin diseases (atopic dermatitis, pemphigus foliaceus and perianal fistulas) and healthy control dogs are required for this study as we are investigating features of naturally occurring skin diseases in the general canine population and comparing this to blood from healthy dogs to identify factors that contribute to the diseased state

    Exclusion Criteria:

    Dogs weighing less than 5kg, dogs less than a year old or greater than 14 years old, pregnant dogs.

    Dogs will be excluded from the healthy control group if they have evidence of skin disease on physical examination or from their history, or if they have evidence of systemic disease (other than age appropriate changes) on their history, physical examination or bloodwork.

    Client Benefits:

    There are no additional costs to you for taking the blood sample. The study will cover the cost of a complete blood count/serum biochemistry health screen panel run on your dog’s blood on the first sample only, and these results will be provided to you.

    Costs for any diagnostics or treatment recommended by your veterinarian resulting from abnormal findings on the blood test or relating to their skin disease are not provided by this study.

    Your animal’s participation in this study does not influence ongoing management or treatment of any medical condition by your veterinarian, and will not change any treatment or outcome for his/her skin disease.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

     

     

  • CSRC Protocol # 110-16

    Status: Currently enrolling

    Description:

    Our overall goal is to measure the incidence of vomiting, gastroesophageal reflux (GER) and regurgitation in dogs after pre-anesthetic administration of acepromazine and dexmedetomdine . These complications can potentially result in severe esophageal damage and aspiration of stomach contents causing pneumonia .

    This study will allow us to identify the most efficient drug regime that reduces the incidence of GER and regurgitation during anesthesia in particular in those patients more predisposed to gastrointestinal complications. The study will also allow us to institute early treatment with antiemetics and gastrointestinal protectants once GER is detected. It is also our aim to raise awareness in regards to these potential complications.

    Inclusion Criteria:

    Healthy dogs that are scheduled to undergo an elective soft tissue or orthopedic procedure that are:

    • 6 months to 8 years of age
    • Male or female
    • weighing 5 kg (11 lb) to 35 kg (77 lb)

    Exclusion Criteria:

    • Dogs will be excluded from this study if they have vomited or regurgitated within a week of the scheduled elective soft tissue or orthopedic procedure .
    • Dogs will also be excluded if the randomized treatment does not provide enough sedation to place an intravenous catheter in a safe and ethical manner.

    Client Benefits:

    Participation in the study will allow us to identify peri-operative regurgitation and reflux earlier than if your pet was not included in this study. If there is evidence of regurgitation during the procedure, your animal will be promptly treated (suction and/or esophageal wash). This study will also provide data of the occurrence of perioperative reflux which would not be otherwise identified. The information will be considered in the postoperative management of your pet. Your pet's participation will also  allow us to gain information which will help in the management of other dogs in the future that undergo general anesthesia

    Contact information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu

     

     

     

     

  • Sponsor: Private Foundation

    IACUC Protocol # G2016-134

    Status:  Currently enrolling

    Description:

    Dogs develop inflammatory bowel disease (IBD) spontaneously, which results in persistent or recurring signs such as weight loss, vomiting, and/or diarrhea, and is characterized by inflammatory cell infiltration in the intestine.

    In both humans and dogs, IBD is considered to be an idiopathic, chronic, relapsing immune-mediated inflammatory disorder of the GI tract that involves the interplay between genes, diet, and the microbes in the intestine. The treatment for IBD in both dogs and humans is similar, and relies on diet, immune suppression.

    The goals of this experiment are: 1) to evaluate the gene expression of the white blood cells in the intestine and the blood of dogs with inflammatory bowel disease compared to normal dogs, and 2) to evaluate the in vitro response to activation of the T cells in the blood and intestine of dogs with IBD and normal dogs, and 3) to determine in vitro if extracellular vesicles (EV) derived from canine mesenchymal stem cells (MSC) or the MSC themselves are able to reduce the inflammation seen in dogs with IBD.

    MSC are cells derived from the tissue around the umbilical cord, which are known to have anti-inflammatory and regenerative properties. EV are nanoparticles released from the MSC, which contain many signaling molecules that are also potentially capable of anti-inflammatory properties.

    Inclusion Criteria:

    IBD group:

    Dogs over 1 year of age and weighing > 5 kg undergoing upper gastrointestinal endoscopy for evaluation of a history of chronic gastrointestinal signs of at least 3 weeks duration (vomiting, diarrhea, and/or weight loss) will be considered. These dogs will have no identifiable cause for their clinical signs on routine diagnostic evaluation (complete blood count, serum chemistry, urinalysis, baseline cortisol). Dogs will need to have had a veterinarian-recommended diet trial for at least 1 week with incomplete resolution of signs, as well as be incompletely responsive to an antibiotic trial with metronidazole or tylosin. Eligible dogs will have had a negative fecal floatation and Giardia ELISA or negative zinc sulfate floatation, or be non-responsive to a treatment course with fenbendazole (50 mg/kg daily for 3 days).

    Control dogs for blood and GI tissue acquisition will include otherwise healthy dogs undergoing endoscopy for foreign body retrieval and weighing > 5 kg. Dogs will have no evidence of systemic disease (change in weight, thirst, urination, activity level), and no history of gastrointestinal signs unrelated to recent foreign body ingestion.

    Exclusion Criteria:

    Dogs with cancer detected on physical examination or diagnostics performed will be excluded. Dogs cannot be on topical or oral short acting steroid therapy (prednisone or prednisolone), other oral immunosuppressants (i.e., azathioprine, cyclosporine), or oral non-steroidal anti-inflammatory (i.e., Rimadyl, Deramaxx) medication for at least 1 week prior to biopsy. Antibiotic therapy will not exclude a patient from enrollment.

    Client Benefits:

    Fees associated with histopathology (microscopic evaluation of the intestinal tissue) performed during the study will be covered during your participation in the study. Costs incurred by additional anesthesia time over that needed for diagnostic biopsy collection or foreign body removal will be covered by the study.

    In the event any complications arise during endoscopy, their management will be covered by you.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu